Jay W. Hooper

8.2k total citations
95 papers, 4.5k citations indexed

About

Jay W. Hooper is a scholar working on Infectious Diseases, Epidemiology and Global and Planetary Change. According to data from OpenAlex, Jay W. Hooper has authored 95 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Infectious Diseases, 28 papers in Epidemiology and 26 papers in Global and Planetary Change. Recurrent topics in Jay W. Hooper's work include Viral Infections and Vectors (57 papers), Viral Infections and Outbreaks Research (55 papers) and Fire effects on ecosystems (26 papers). Jay W. Hooper is often cited by papers focused on Viral Infections and Vectors (57 papers), Viral Infections and Outbreaks Research (55 papers) and Fire effects on ecosystems (26 papers). Jay W. Hooper collaborates with scholars based in United States, China and Chile. Jay W. Hooper's co-authors include David Custer, Connie S. Schmaljohn, E. Ashley Thompson, Joseph W. Golden, Rebecca L. Brocato, Connie S. Schmaljohn, Matthew Josleyn, A. L. Schmaljohn, Thomas Larsen and Christopher Hammerbeck and has published in prestigious journals such as Nature Medicine, PLoS ONE and Journal of Virology.

In The Last Decade

Jay W. Hooper

94 papers receiving 4.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jay W. Hooper United States 40 2.8k 1.3k 1.2k 1.2k 800 95 4.5k
Jason Paragas United States 31 2.7k 1.0× 474 0.4× 1.3k 1.0× 621 0.5× 110 0.1× 50 4.0k
Hideki Ebihara United States 49 5.2k 1.9× 125 0.1× 2.0k 1.6× 634 0.5× 535 0.7× 139 6.7k
Ken Maeda Japan 30 2.0k 0.7× 364 0.3× 1.1k 0.9× 237 0.2× 176 0.2× 233 3.5k
Frank T. Hufert Germany 32 1.3k 0.5× 353 0.3× 1.1k 0.9× 720 0.6× 66 0.1× 84 3.2k
César G. Albariño United States 39 3.8k 1.4× 150 0.1× 705 0.6× 313 0.3× 507 0.6× 95 4.4k
Thomas Larsen United States 27 2.6k 0.9× 333 0.3× 974 0.8× 483 0.4× 157 0.2× 34 3.4k
Michèle Bouloy France 44 5.1k 1.8× 124 0.1× 1.1k 0.9× 1.1k 1.0× 1.5k 1.9× 121 6.9k
Paul-Pierre Pastoret Belgium 35 1.1k 0.4× 644 0.5× 1.4k 1.2× 452 0.4× 57 0.1× 204 3.8k
Cynthia A. Rossi United States 31 1.8k 0.6× 215 0.2× 343 0.3× 630 0.5× 366 0.5× 59 2.5k
Gerald A. Eddy United States 26 1.5k 0.5× 887 0.7× 607 0.5× 239 0.2× 85 0.1× 63 2.2k

Countries citing papers authored by Jay W. Hooper

Since Specialization
Citations

This map shows the geographic impact of Jay W. Hooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay W. Hooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay W. Hooper more than expected).

Fields of papers citing papers by Jay W. Hooper

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay W. Hooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay W. Hooper. The network helps show where Jay W. Hooper may publish in the future.

Co-authorship network of co-authors of Jay W. Hooper

This figure shows the co-authorship network connecting the top 25 collaborators of Jay W. Hooper. A scholar is included among the top collaborators of Jay W. Hooper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jay W. Hooper. Jay W. Hooper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hooper, Jay W., Steven A. Kwilas, Matthew Josleyn, et al.. (2024). Phase 1 clinical trial of Hantaan and Puumala virus DNA vaccines delivered by needle-free injection. npj Vaccines. 9(1). 221–221. 4 indexed citations
2.
Golden, Joseph W., Steven A. Kwilas, & Jay W. Hooper. (2024). Glycoprotein-Specific Polyclonal Antibodies Targeting Machupo Virus Protect Guinea Pigs against Lethal Infection. Vaccines. 12(6). 674–674. 1 indexed citations
3.
Chapman, Rosamund, et al.. (2023). Improved DNA Vaccine Delivery with Needle-Free Injection Systems. Vaccines. 11(2). 280–280. 56 indexed citations
4.
Zhang, Qi, Lin Cheng, Jiwan Ge, et al.. (2022). Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Frontiers in Immunology. 13. 980435–980435. 12 indexed citations
5.
Suschak, John J., Sandra L. Bixler, Catherine V. Badger, et al.. (2022). A DNA vaccine targeting VEE virus delivered by needle-free jet-injection protects macaques against aerosol challenge. npj Vaccines. 7(1). 46–46. 13 indexed citations
6.
Golden, Joseph W., Xiankun Zeng, Aura R. Garrison, et al.. (2021). Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease. Journal of General Virology. 102(5). 5 indexed citations
7.
Brocato, Rebecca L., Steven A. Kwilas, Matthew Josleyn, et al.. (2021). Small animal jet injection technique results in enhanced immunogenicity of hantavirus DNA vaccines. Vaccine. 39(7). 1101–1110. 11 indexed citations
8.
Brocato, Rebecca L., Xiankun Zeng, Janice A. Williams, et al.. (2020). Disruption of Adaptive Immunity Enhances Disease in SARS-CoV-2-Infected Syrian Hamsters. Journal of Virology. 94(22). 46 indexed citations
9.
Golden, Joseph W., Xiankun Zeng, Aura R. Garrison, et al.. (2020). Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease. JCI Insight. 5(19). 132 indexed citations
10.
11.
Perley, Casey C., Rebecca L. Brocato, Hua Wu, et al.. (2020). Anti-HFRS Human IgG Produced in Transchromosomic Bovines Has Potent Hantavirus Neutralizing Activity and Is Protective in Animal Models. Frontiers in Microbiology. 11. 832–832. 19 indexed citations
12.
Stein, Derek R., Joseph W. Golden, Bryan D. Griffin, et al.. (2017). Human polyclonal antibodies produced in transchromosomal cattle prevent lethal Zika virus infection and testicular atrophy in mice. Antiviral Research. 146. 164–173. 20 indexed citations
13.
Bengtsson, Karin Lövgren, Haifeng Song, Linda Stertman, et al.. (2016). Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. Vaccine. 34(16). 1927–1935. 94 indexed citations
14.
Martins, Karen, John H. Carra, Christopher L. Cooper, et al.. (2014). Cross-Protection Conferred by Filovirus Virus-Like Particles Containing Trimeric Hybrid Glycoprotein. Viral Immunology. 28(1). 62–70. 18 indexed citations
15.
16.
Hooper, Jay W., et al.. (2011). Efficient production of Hantaan and Puumala pseudovirions for viral tropism and neutralization studies. Virology. 423(2). 134–142. 25 indexed citations
17.
Flick, Kirsten, Jay W. Hooper, Connie S. Schmaljohn, et al.. (2003). Rescue of hantaan virus minigenomes. Virology. 306(2). 219–224. 77 indexed citations
18.
Hooper, Jay W., et al.. (2001). Vaccines Against Hantaviruses. Current topics in microbiology and immunology. 256. 171–191. 48 indexed citations
19.
Hooper, Jay W., David Custer, Connie S. Schmaljohn, & A. L. Schmaljohn. (2000). DNA Vaccination with Vaccinia Virus L1R and A33R Genes Protects Mice against a Lethal Poxvirus Challenge. Virology. 266(2). 329–339. 156 indexed citations
20.
Hooper, Jay W., Kurt I. Kamrud, Fredrik Elgh, David Custer, & Connie S. Schmaljohn. (1999). DNA Vaccination with Hantavirus M Segment Elicits Neutralizing Antibodies and Protects against Seoul Virus Infection. Virology. 255(2). 269–278. 112 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jason Paragas Breakdown of academic impact, for papers by Hideki Ebihara Breakdown of academic impact, for papers by Ken Maeda Breakdown of academic impact, for papers by Frank T. Hufert Breakdown of academic impact, for papers by César G. Albariño Breakdown of academic impact, for papers by Thomas Larsen Breakdown of academic impact, for papers by Michèle Bouloy Breakdown of academic impact, for papers by Paul-Pierre Pastoret Breakdown of academic impact, for papers by Cynthia A. Rossi Breakdown of academic impact, for papers by Gerald A. Eddy
Rankless by CCL
2026